ClinicalTrials.gg
Not yet recruitingNCT07745725Updated Aug 4, 2026

A Phase II Study of TollB-001 Tablets in Systemic Sclerosis

A Phase 2 interventional study of TollB-001 Tablet and Placebo in Systemic Sclerosis (SSc), sponsored by Toll Biotech Co. Ltd. (Beijing). Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Toll Biotech Co. Ltd. (Beijing) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Scleroderma, Systemic with a site in China — 64 open to participants now, 69 under way, 4 of them phase 3. Scleroderma, Systemic · China.

Planned enrollment
27th of 77
36 · median 20
Started
2026
with 19 others
Phase 2
4 of 82
3 open now
Primary completion
2027-10
later than 41 of 68 live
Registered
80th of 82
by date

Among the 82 studies in Scleroderma, Systemic with a site in China, this one is the 27th largest by planned enrollment of the 77 interventional ones that give a count, is one of 20 that started in 2026, is one of 4 in phase 2, reaches primary completion later than 41 of the 68 other live ones, and was the 80th registered.

Scleroderma, Systemic

613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

64 of the 82 studies in Scleroderma, Systemic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Scleroderma, Systemic with a site in China, or all of them as a file.
02

Study summary

The goal of this Phase II study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of TollB-001 Tablets in adults aged 18 to 70 years (male or female) with systemic sclerosis (SSc).

Read the detailed description

Study Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of TollB-001 in Adult Patients with Systemic Sclerosis (SSc) Study Design: This is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of TollB-001 in adult patients with systemic sclerosis (SSc).

Sample Size and Target Population: A total of 36 patients with SSc are planned for enrollment. Eligible patients must have a disease duration of ≤ 60 months from the first onset of non-Raynaud's phenomenon and a modified Rodnan Skin Score (mRSS) between 10 and 40 (inclusive) at the screening visit.

Study Phases: The study consists of three sequential phases:

Screening Period: Up to 28 days

Treatment Period: 90 days, comprising:

Single-Dose Phase: 3 days (dosing on Day 1 only) Multiple-Dose Phase: 87 days (consecutive daily dosing from Day 4 through Day 87, for a total of 84 days of dosing) Follow-up Period: 28 days following the last dose

03

Conditions studied

  • Systemic Sclerosis (SSc)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 70 years (inclusive), male or female.
  2. Diagnosis of systemic sclerosis (SSc) according to the 2013 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) classification criteria.
  3. Meeting the classification criteria for diffuse cutaneous systemic sclerosis (dcSSc) as defined in the 2022 Chinese Guideline for the Diagnosis and Treatment of Systemic Sclerosis.
  4. Evidence of active disease at screenin.
  5. Female participants of and male participants must use effective during the study and for 3 months after the last dose of study drug. Male participants whose partners are females of must agree to use effective contraception and refrain from donating sperm during the study and for 3 months after the last dose. Female participants of childbearing potential must have a negative pregnancy test.
  6. Able to swallow all study medications.
  7. Willing and able to comply with the study protocol (e.g., able to understand and complete questionnaires, adhere to visit schedules, and take study medication) and provide signed .

Exclusion criteria

Exclusion Criteria:

  1. Known to any active ingredient or of the study drug, or to drugs of the same class.
  2. History of scleroderma renal crisis within 6 months prior to randomization.
  3. chronic intermittent bleeding within 4 weeks prior to screening (e.g., active gastric antral vascular ectasia, active peptic ulcer, or duodenal ulcer), or participants at risk of bleeding.
  4. Any active or history of malignancy.
  5. Presence of severe, uncontrolled diseases.
  6. Major surgery within 8 weeks prior to randomization, or expected to undergo major surgery after enrollment.
  7. Drug or alcohol abuse or dependence at screening, or a history of drug or alcohol abuse or dependence within 6 months prior to randomization.
  8. Participation in another clinical trial within 3 months prior to the date of , or planning to participate in another clinical trial during the study period.
  9. Participants who, in the investigator's judgment, are unsuitable for participation in this clinical trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    TollB-001 Tablet Low Dose

    Eligible participants will be randomized to receive TollB-001 tablet low dose, administered once daily for 12 consecutive weeks.

    Drug: TollB-001 Tablet

  • Experimental
    TollB-001 Tablet High Dose

    Eligible participants will be randomized to receive TollB-001 tablet high dose, administered once daily for 12 consecutive weeks.

    Drug: TollB-001 Tablet

  • Placebo comparator
    Placebo

    Eligible participants will be randomized to receive matching placebo, administered once daily for 12 consecutive weeks.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Rodnan Skin Score (mRSS)

    Time frame: up to 12 weeks

Secondary outcomes

  1. Composite Response Index in Systemic Sclerosis (CRISS)

    Time frame: up to 12 weeks

  2. Forced Vital Capacity (FVC)

    Time frame: up to 12 weeks

  3. Health Assessment Questionnaire- Disability Index (HAQ-DI)

    Time frame: up to 12 weeks

  4. Patient Global Assessment (PtGA)

    Time frame: up to 12 weeks

  5. Incidence and Severity of Adverse Events

    Time frame: up to 12 weeks

  6. Incidence and Severity of Adverse Reactions

    Time frame: up to 12 weeks

  7. Incidence of Serious Adverse Events

    Time frame: up to 12 weeks

  8. Incidence of Serious Adverse Reactions

    Time frame: up to 12 weeks

  9. The four major vital signs, including body temperature, pulse (heart rate), respiration, and blood pressure.

    Time frame: up to 12 weeks

  10. The 12-lead electrocardiogram (ECG) includes parameters such as heart rate, RR interval, PR interval, QT interval, QRS interval, and the corrected QT interval (QTcf, where QTcf = QT / RR^0.33).

    Time frame: up to 12 weeks

  11. Routine blood test includes parameter such as white blood cell, lymphocyte count and percentage, neutrophil count and percentage, monocyte count and percentage, eosinophil count, basophil count, , red blood cell, hemoglobin, hematocrit, platelet count.

    Time frame: up to 12 weeks

  12. Blood biochemical parameters such as: aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin, indirect bilirubin, total protein, albumin, alkaline phosphatase, gamma-glutamyl transferase (GGT) and urea, etc.

    Time frame: up to 12 weeks

  13. Coagulation function parameters suc as the International Normalized Ratio (INR), activated partial thromboplastin time (APTT), prothrombin time (PT), and fibrinogen.

    Time frame: up to 12 weeks

07

Study locations

2 sites
  • Toll Biotech, 2108-B007, No. 9 West Beisihuan Road, Haidian District, Beijing, People's Republic of China
    Beijing, Beijing Municipality 100083, China
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 102206, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Oct 2027, 14 months later.

Of 48 phase 2 interventional studies under Scleroderma, Systemic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2026
First posted
Aug 4, 2026
StartEst.
Aug 2026
Primary completionEst.
Oct 2027
CompletionEst.
Feb 2028
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07745725
Lead sponsor
Toll Biotech Co. Ltd. (Beijing)
Responsible party
Sponsor
First posted
Aug 4, 2026
Start date
Aug 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Aug 4, 2026

Study contacts

Wang weili
Contact
wangweili@toll-biotech.com
010-80710966

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TOLLB-001

Start the discussion